Skip to main content
Clinical Trials/NCT01133236
NCT01133236
Completed
Not Applicable

Randomized Clinical Trial to Assess the Effect of Fluid and Salt Restriction on the Management of Patients Hospitalized Due to Decompensated Heart Failure

Hospital de Clinicas de Porto Alegre0 sites80 target enrollmentAugust 2009
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Hospital de Clinicas de Porto Alegre
Enrollment
80
Primary Endpoint
Bodyweight loss
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The non-pharmacological measures that are widely practiced and recommended for HF patients, such as salt and water restriction, specially at moments of disease decompensation, still lack clearer evidence of their therapeutic effect.

Detailed Description

Heart Failure Clinics, healthcare structures formed by a multidisciplinary team specialized in the disease, have demonstrated to provide benefits to patients through multiple non-pharmacological interventions, among them fluid and salt restriction. Sodium restriction has a class I recommendation and evidence level C, that is, general agreement that the intervention is beneficial, useful and effective, evidenced by consensus, expert opinion, small studies, retrospective studies or registries. Sodium restriction becomes even more controversial when we consider evidence suggesting the benefit of non-salt restriction or treatments with salt administration, in the form of hypertonic solutions. In face of literature evidence not showing conclusive results about the benefit of sodium and fluid restriction, we designed this study in order to assess the effect of fluid and salt restriction on the management of patients hospitalized due to decompensated heart failure

Registry
clinicaltrials.gov
Start Date
August 2009
End Date
September 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eneida Rejane Rabelo da Silva

Professor, PhD.

Hospital de Clinicas de Porto Alegre

Eligibility Criteria

Inclusion Criteria

  • Patients of both sexes, with age equal to or above 18 years, diagnosed with decompensated HR (systolic dysfunction), according to the Boston Criteria (score \> 8 points), who agree to participate in the study and sign an informed consent form.

Exclusion Criteria

  • Patients presenting with endogenous creatinine clearance (ECC) values lower than or equal to 50-60 mL/min (obtained by the Cockcroft-Gault equation) at hospital admission, cardiogenic shock, survival compromised by another evolving disease, those with difficulty complying with treatment (dementia, cognitive deficit).

Outcomes

Primary Outcomes

Bodyweight loss

Time Frame: 7 days

Daily weight on a digital scale

Clinical stability

Time Frame: Seven days.

Clinical assessment daily for 7 days.

Secondary Outcomes

  • Health state evaluation.(30 days)
  • Evaluation of thirst sensation.(Seven days)
  • Re-hospitalizations.(30 days)

Similar Trials